Mutations associated with cystic fibrosis
First Claim
1. A composition consisting of a plurality of labeled nucleic acid molecules that each consist of a fragment of a cystic fibrosis transmembrane conductance regulator gene and that specifically hybridize to a mutant but not a wild-type cystic fibrosis transmembrane conductance regulator gene, wherein at least one of the labeled nucleic acid molecules contains a cystic fibrosis transmembrane conductance regulator 2957delT mutation, and wherein the label comprises one of a radionucleotide, a fluorophore, a chemiluminescent agent, a microparticle, an enzyme, a colorimetric label, a magnetic label, a hapten, a molecular beacon, or an aptamer beacon.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides novel mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that can be used for a more accurate diagnosis of cystic fibrosis (CF) and CF related disorders. Methods for testing a sample obtained from a subject to determine the presence of one or more mutations in the CFTR gene are provided wherein the presence of one or more mutations indicates that the subject has CF or a CF related disorder, or is a carrier of a CFTR mutation.
29 Citations
12 Claims
- 1. A composition consisting of a plurality of labeled nucleic acid molecules that each consist of a fragment of a cystic fibrosis transmembrane conductance regulator gene and that specifically hybridize to a mutant but not a wild-type cystic fibrosis transmembrane conductance regulator gene, wherein at least one of the labeled nucleic acid molecules contains a cystic fibrosis transmembrane conductance regulator 2957delT mutation, and wherein the label comprises one of a radionucleotide, a fluorophore, a chemiluminescent agent, a microparticle, an enzyme, a colorimetric label, a magnetic label, a hapten, a molecular beacon, or an aptamer beacon.
-
7. A kit consisting of a plurality of labeled nucleic acid molecules that each consist of a fragment of a cystic fibrosis transmembrane conductance regulator gene and that specifically hybridize to a mutant but not a wild-type cystic fibrosis transmembrane conductance regulator gene, wherein at least one of the labeled nucleic acid molecules contains a cystic fibrosis transmembrane conductance regulator 2957delT mutation, wherein the label comprises one of a radionucleotide, a fluorophore, a chemiluminescent agent, a microparticle, an enzyme, a colorimetric label, a magnetic label, a hapten, a molecular beacon, or an aptamer beacon;
- and
instructions for indicating that a subject has cystic fibrosis, or is at risk of developing cystic fibrosis when the subject is homozygous for the 2957delT mutation, or is a carrier of cystic fibrosis when the subject is heterozygous for the 2957delT mutation. - View Dependent Claims (8, 9, 10, 11, 12)
- and
Specification
-
- Resources
-
Current AssigneeLaboratory Corporation Of America Holdings
-
Original AssigneeLaboratory Corporation Of America Holdings
-
InventorsRohlfs, Elizabeth, Sirko-Osadsa, Deborah Alexa, Rosenblum, Lynne, Nagan, Narasimhan, Zhou, Zhaoqing, Heim, Ruth
-
Primary Examiner(s)HANEY, AMANDA MARIE
-
Application NumberUS14/976,790Publication NumberTime in Patent Office491 DaysField of SearchNoneUS Class CurrentCPC Class CodesC12Q 1/6816 characterised by the detect...C12Q 1/6883 for diseases caused by alte...C12Q 2535/125 Allele specific primer exte...C12Q 2565/627 being a mass spectrometerC12Q 2600/112 Disease subtyping, staging ...C12Q 2600/156 Polymorphic or mutational m...C12Q 2600/16 Primer sets for multiplex a...G01N 2800/382 Cystic fibrosisG01N 33/6872 Intracellular protein regul...
